The potential cancer risk associated with GH treatment has been an ongoing concern since its introduction due to the role of the GH-IGF-1 signaling pathways in fundamental cellular processes of mitosis, growth and cell survival, along with supporting experimental evidence of its impact on tumor formation (21, 22). This evidence concerns the gene GH1 and neoplasm.